MX377570B - Proteínas de fusión ctla4 para el tratamiento de la diabetes. - Google Patents

Proteínas de fusión ctla4 para el tratamiento de la diabetes.

Info

Publication number
MX377570B
MX377570B MX2015000237A MX2015000237A MX377570B MX 377570 B MX377570 B MX 377570B MX 2015000237 A MX2015000237 A MX 2015000237A MX 2015000237 A MX2015000237 A MX 2015000237A MX 377570 B MX377570 B MX 377570B
Authority
MX
Mexico
Prior art keywords
ctla4
diabetes
treatment
fusion proteins
ctla4 fusion
Prior art date
Application number
MX2015000237A
Other languages
English (en)
Other versions
MX2015000237A (es
Inventor
Tihamer Orban
Original Assignee
Orban Biotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orban Biotech Llc filed Critical Orban Biotech Llc
Publication of MX2015000237A publication Critical patent/MX2015000237A/es
Publication of MX377570B publication Critical patent/MX377570B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

En el presente documento se proporciona un método para tratar, prevenir, o retrasar la progresión de la autoinmunidad de la diabetes mellitus tipo 1 al administrar una cantidad eficaz de una molécula de antígeno 4 asociado al linfocito T citotóxico (CTLA4, por sus siglas en inglés). La molécula CTLA4 puede ser una proteína de fusión de una región extracelular de CTLA4 y de una inmunoglobulina, como abatacept.
MX2015000237A 2012-06-27 2013-06-27 Proteínas de fusión ctla4 para el tratamiento de la diabetes. MX377570B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201213534560A 2012-06-27 2012-06-27
PCT/US2013/048237 WO2014004857A1 (en) 2012-06-27 2013-06-27 Ctla4 fusion proteins for the treatment of diabetes

Publications (2)

Publication Number Publication Date
MX2015000237A MX2015000237A (es) 2015-08-14
MX377570B true MX377570B (es) 2025-03-10

Family

ID=49783866

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015000237A MX377570B (es) 2012-06-27 2013-06-27 Proteínas de fusión ctla4 para el tratamiento de la diabetes.

Country Status (11)

Country Link
US (3) US20140099306A1 (es)
EP (2) EP2866823A4 (es)
JP (1) JP2015522026A (es)
KR (1) KR20150033703A (es)
CN (2) CN113138279A (es)
AU (2) AU2013284460A1 (es)
CA (1) CA2877986A1 (es)
IN (1) IN2015DN00214A (es)
MX (1) MX377570B (es)
WO (1) WO2014004857A1 (es)
ZA (1) ZA201500228B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8735359B2 (en) * 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
WO2014004857A1 (en) 2012-06-27 2014-01-03 Orban Biotech Llc Ctla4 fusion proteins for the treatment of diabetes
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
EP3283508B1 (en) 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
JP7749319B2 (ja) 2017-10-10 2025-10-06 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用
PT3697810T (pt) 2017-10-18 2026-02-19 Alpine Immune Sciences Inc Proteínas imunomoduladoras de ligandos icos variantes e composições e métodos relacionados
US11547712B2 (en) 2017-11-20 2023-01-10 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
BR112020013236A2 (pt) 2018-01-03 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
CN111819193A (zh) 2018-01-05 2020-10-23 西奈山伊坎医学院 增加胰腺β细胞增殖的方法、治疗方法以及组合物
AU2019240065A1 (en) 2018-03-20 2020-09-24 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
CA3128425A1 (en) 2019-02-04 2020-08-13 Assistance Publique-Hopitaux De Paris Method for treating checkpoint inhibitors induced adverse events
IL288024B2 (en) * 2019-05-14 2025-12-01 Provention Bio Inc Methods and compositions for preventing type
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
KR100238712B1 (ko) 1991-06-27 2000-01-15 스티븐 비. 데이비스 씨티엘에이4 수용체,그를 함유한 연합단백질 및 그의 용도
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
ZA929870B (en) 1991-12-23 1993-08-18 Duphar Int Res Adjuvants
FR2702373B1 (fr) 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
US6719972B1 (en) 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
US6110746A (en) 1995-06-30 2000-08-29 Yeda Research And Development Co. Ltd. Peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits
US20030190323A1 (en) 1995-07-05 2003-10-09 Yeda Research And Development Co. Ltd. Preparations and methods for the treatment of T cell mediated diseases
US7041634B2 (en) * 1995-09-27 2006-05-09 Emory University Method of inhibiting immune system destruction of transplanted viable cells
EP0781559B1 (en) 1995-11-30 2007-02-07 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Oil adjuvant vaccine and method for preparing same
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US6797269B2 (en) 1998-04-03 2004-09-28 Osiris Therapeutics, Inc. Mesenchymal stem cells as immunosuppressants
CN101255192A (zh) 2000-05-26 2008-09-03 布里斯托尔-迈尔斯斯奎布公司 可溶性ctla4突变体分子及其应用
HRP20030071B1 (hr) 2000-07-03 2014-01-03 Bristol-Myers Squibb Company Postupci za lijeäśenje reumatskih bolesti uporabom topljivih ctla4 mutantnih molekula
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
WO2002053106A2 (en) 2001-01-05 2002-07-11 Joslin Diabetes Center, Inc. Autoantigen composition
CA2433877C (en) * 2001-01-17 2014-11-18 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
MXPA03010568A (es) * 2001-05-23 2005-03-07 Squibb Bristol Myers Co Metodos para proteger trasplantes alogenicos de celulas de isletas usando moleculas mutantes ctla4 solubles.
EP1440084B1 (en) 2001-10-24 2010-01-06 University College Cardiff Consultants Ltd. Sperm factor sequences
US20040136998A1 (en) * 2002-10-30 2004-07-15 Bander Neil H. Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen
US8278420B2 (en) * 2005-08-06 2012-10-02 Qinghua Wang Composition and method for prevention and treatment of type I diabetes
EP1930415A4 (en) 2005-09-30 2009-05-13 Univ Kyoto DEVELOPMENT OF A SCREENING METHOD FOR A CONNECTABLE COMPOUND FOR IMPROVING THE PRODUCTION OF A REGULATORY T-CELL AND METHOD FOR THE PRODUCTION OF A REGULATORY T-CELL USING AN IMMUNOSUPPRESSIVE MAKROLIDANTIBIOTIC
WO2007127787A2 (en) 2006-04-25 2007-11-08 Joslin Diabetes Center, Inc. Insulin autoantigen-specific regulatory cd4+ t cells
US7528111B2 (en) * 2006-05-12 2009-05-05 Bristol-Myers Squibb Company Method of vaccinating subjects receiving immune modulating therapy
WO2009029847A1 (en) 2007-08-30 2009-03-05 Curedm, Inc. Compositions and methods of using proislet peptides and analogs thereof
US9176122B2 (en) 2008-03-24 2015-11-03 University Of South Florida Biomarkers for predicting response to immunosuppressive therapy
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
EP2588123A2 (en) 2010-06-30 2013-05-08 Compugen Ltd. C1orf32 for the treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
WO2012015903A1 (en) 2010-07-27 2012-02-02 Bayhill Therapeutics, Inc. Treatment of type i diabetes mellitus (t1dm) in young newly diagnosed patients
EP2704738A1 (en) * 2011-05-06 2014-03-12 Diamedica Inc. Compositions and methods for treating diabetes
US20130316375A1 (en) 2012-05-24 2013-11-28 Orban Biotech Llc Diabetes biomarkers
US8735359B2 (en) * 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
WO2014004857A1 (en) 2012-06-27 2014-01-03 Orban Biotech Llc Ctla4 fusion proteins for the treatment of diabetes
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence

Also Published As

Publication number Publication date
US20140099306A1 (en) 2014-04-10
CA2877986A1 (en) 2014-01-03
MX2015000237A (es) 2015-08-14
AU2018201965B2 (en) 2019-11-21
JP2015522026A (ja) 2015-08-03
CN113138279A (zh) 2021-07-20
KR20150033703A (ko) 2015-04-01
WO2014004857A1 (en) 2014-01-03
EP2866823A4 (en) 2016-03-02
US10233242B2 (en) 2019-03-19
EP3811966A1 (en) 2021-04-28
US11286303B2 (en) 2022-03-29
US20190211105A1 (en) 2019-07-11
EP2866823A1 (en) 2015-05-06
AU2018201965A1 (en) 2018-04-12
ZA201500228B (en) 2016-01-27
CN104519900A (zh) 2015-04-15
AU2013284460A1 (en) 2015-01-29
IN2015DN00214A (es) 2015-06-12
US20150104451A1 (en) 2015-04-16

Similar Documents

Publication Publication Date Title
MX377570B (es) Proteínas de fusión ctla4 para el tratamiento de la diabetes.
HK1212253A1 (en) Combinations of modalities for the treatment of diabetes
UA118029C2 (uk) Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
PE20171107A1 (es) Anticuerpos mejorados contra il-6
PE20211272A1 (es) POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
MX344971B (es) Anticuerpos anti-ctla4 humanizados.
PE20141188A1 (es) Polipeptidos anticuerpos que antagonizan cd40
HK1220205A1 (zh) 修饰的t淋巴细胞
MD20170031A2 (ro) Anticorpi anti-LAG3 şi fragmente de legare a antigenului
WO2011113019A3 (en) Ctla4 proteins and their uses
BR112015013127A2 (pt) imunoterapia com agentes de ligação
PE20140247A1 (es) Anticuerpos anti-cd38
SG10201805411YA (en) Chimeric antigen receptors
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
WO2015143123A3 (en) Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof
WO2014140374A3 (en) Monovalent cd27 antibodies
PH12016501937A1 (en) Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
PE20170142A1 (es) Proteina de fusion que inhibe angiogenesis o crecimiento y uso de la misma
EP4406550A3 (en) Antibodies to cd40 with enhanced agonist activity
MX381278B (es) Composición para la estimulación ovárica controlada.
MA40182A (fr) NOUVEL ANTICORPS ANTI-Tie2 HUMAIN
PL393578A1 (pl) Przeciwnowotworowe białko fuzyjne
NZ721015A (en) Mutant fragments of ospa and methods and uses relating thereto
UA117493C2 (uk) Гібридна конструкція, що включає антигенсполучний фрагмент, специфічний до сироваткового альбуміну, й ефекторний компонент, та способи її одержання
PH12014502352A1 (en) Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition

Legal Events

Date Code Title Description
FG Grant or registration